Business
Rakovina Therapeutics Announces Three-Month Q3 ended September 30, 2025 Financial Results and Provides Corporate Update
All dollar amounts reflected in Canadian dollars ...
About this update from Rakovina Therapeutics Inc
[{"type":"text","content":"Rakovina Therapeutics Announces Three-Month Q3 ended September 30, 2025 Financial Results and Provides Corporate Update\n\n\n\n\n\n All\n \n\n\n\n dollar\n \n\n\n\n amounts\n \n\n\n\n reflected\n \n\n\n\n in\n \n\n\n\n Canadian\n \n\n\n\n dollars\n \n\n\n\n unless\n \n\n\n\n otherwise\n \n\n\n\n stated.\n \n\n\n\n VANCOUVER, British Columbia, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced its financial results for the three months ended September 30, 2025\n \n (“Q3 2025”)\n \n , and provided an update on recent corporate developments.\n \n\n\n Q3 2025 Financial Highlights\n \n\n\n\n Reported a net loss of\n \n $1,781,757\n \n .\n \n\n\n\n\n Research and development (R&D) expenses\n \n were\n \n $1,102,371\n \n , reflecting continued advancement of AI-powered drug candidates.\n \n\n\n\n\n General and administrative (G&A) expenses\n \n were\n \n $539,174\n \n including investor & public relations and exchange-related fees.\n \n\n\n\n\n Cash and cash equivalents\n \n as at September 30, 2025 were\n \n $822,293\n \n .\n \n\n\n “Over the past several months, Rakovina Therapeutics has delivered a series of meaningful scientific and corporate milestones that underscore the strength of our AI-enabled DDR pipeline and the growing global interest in our programs,” stated Jeffrey Bacha, Rakovina Therapeutics executive chairman. “From compelling CNS-penetrant ATR data at AACR-NCI-EORTC to multiple presentations at the Society for Neuro-Oncology Annual Meeting, together with increased visibility at leading investor and industry conferences and the advancement of strategic collaborations such as our NanoPalm joint-venture initiative, we are entering 2026 with significant momentum. These achievements not only validate the depth of our science but also position the company for the next phase of growth as we work to bring transformative therapies to patients in need.”\n \n\n\n Recent Corporate Highlights\n \n\n\n\n On November 24, 2025, the Company announced the presentation of two scientific posters at the 2025 Society for Neuro-Oncology Annual Meeting in Honolulu, Hawaii. The posters provid...